Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.46 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNG | P07510 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704995 | 0.90 | ROCK2 (0.53) | ROCK2CYP3A4CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL21158863 | 0.86 | ROCK2 (0.53) | ROCK2CYP3A4CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL18390255 | 0.84 | ROCK2 (0.55) | ROCK2CYP3A4LMNATSHRMAPK1 | |
| SCHEMBL20353685 | 0.84 | CHRM1 (0.51) | ROCK2CYP3A4TSHRNPSR1MEN1 | |
| SCHEMBL20160594 | 0.81 | ROCK2 (0.54) | ROCK2CYP3A4CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL22812215 | 0.81 | ROCK2 (0.52) | ROCK2CYP3A4CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL20070510 | 0.79 | CYP3A4 (0.55) | ROCK2CYP3A4CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL20148581 | 0.75 | ROCK2 (0.54) | ROCK2CYP3A4CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL20148583 | 0.75 | CHRM1 (0.51) | KMT2ACHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL20349547 | 0.75 | CES2 (0.43) | LMNARETKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | ROCK2 581/4885CYP3A4 3158/4885CACNA2D1 2786/4885 |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | ROCK2 581/4885CYP3A4 3158/4885CACNA2D1 2786/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | ROCK2 581/4885CYP3A4 3158/4885CACNA2D1 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.